AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
ABBV News
Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on AbbVie (ABBV – Research Report). The associated price target remains the same with $...
AbbVie (ABBV) announced that Emrelis has been granted accelerated approval by the U.S. Food and Drug Administration for the treatment of adult patients with loc...
Citi on Wednesday upgraded Regeneron (NASDAQ:REGN) and downgraded AbbVie (NYSE:ABBV), citing varying risks for the U.S. pharma majors from the Trump administrat...
Analyst ratings
60%
of 30 ratingsMore ABBV News
AbbVie (ABBV) and ADARx Pharmaceuticals, a late clinical-stage biotechnology company developing next-generation RNA therapeutics, announced a collaboration and...
Advertisement AbbVie ( ) First Quarter 2025 Results Key Financial Results Revenue: US$13.3b (up 8.4% from 1Q 2024). Net income: US$1.28b (down 6.1% from 1Q...
